At present, Ki-67 proliferation indices are not routinely performed for every specimen with ER+/HER2− early breast cancer due to its limited value for treatment decisions due to inconsistent and questionable analytical validity and reproducibility [47], as recently outlined by the International Ki-67 in Breast Cancer working group [55]. Here, MKI67 is linked to breast carcinoma.